{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T03:51:19Z","timestamp":1765079479462,"version":"3.44.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.atherosclerosis.2022.06.1022","type":"journal-article","created":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T17:12:07Z","timestamp":1656868327000},"page":"45-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Percutaneous coronary intervention with peripheral artery disease in the contemporary era: Still life or limb?"],"prefix":"10.1016","volume":"355","author":[{"given":"Rajesh","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin R.","family":"Bainey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2022","series-title":"Outcome after Percutaneous Coronary Intervention with Contemporary Stents in Patients with Concomitant Peripheral Arterial Disease: A Patient-Level Pooled Analysis of Four Randomized Trials","author":"Pinxterhuis","key":"10.1016\/j.atherosclerosis.2022.06.1022_bib1"},{"year":"1994","series-title":"A Definition of Initial, Fatty Streak, and Intermediate Lesions of Atherosclerosis. A Report from the Committee on Vascular Lesions of the Council on Arteriosclerosis","author":"Stary","key":"10.1016\/j.atherosclerosis.2022.06.1022_bib2"},{"key":"10.1016\/j.atherosclerosis.2022.06.1022_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.cjco.2021.03.005","article-title":"Medical management of peripheral arterial disease: deciphering the intricacies of therapeutic options","author":"Sunner","year":"2021","journal-title":"CJC open"},{"key":"10.1016\/j.atherosclerosis.2022.06.1022_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejvs.2011.09.016","article-title":"Two-year vascular hospitalisation rates and associated costs in patients at risk of atherothrombosis in France and Germany: highest burden for peripheral arterial disease","author":"Smolderen","year":"2012","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.atherosclerosis.2022.06.1022_bib5","article-title":"One-year costs associated with cardiovascular disease in Canada: insights from the REduction of Atherothrombosis for Continued Health (REACH) registry","author":"Smolderen","year":"2010","journal-title":"Can J Cardiol"},{"journal-title":"Eur Heart J","year":"2021","author":"Giacoppo","key":"10.1016\/j.atherosclerosis.2022.06.1022_bib6"},{"journal-title":"J Vasc Surg","article-title":"Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions","year":"2007","key":"10.1016\/j.atherosclerosis.2022.06.1022_bib7"},{"key":"10.1016\/j.atherosclerosis.2022.06.1022_bib8","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.06.1022_bib9","article-title":"Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial","author":"Jukema","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2022.06.1022_bib10","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.117.032031","article-title":"Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG outcome","author":"Verma","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.06.1022_bib11","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2022.06.1022_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.119.044775","article-title":"Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58","author":"Bonaca","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.06.1022_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","author":"Hernandez","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.atherosclerosis.2022.06.1022_bib14","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008018","article-title":"Clinical outcomes in patients with type 2 diabetes mellitus and peripheral artery disease: results from the EXSCEL trial","author":"Badjatiya","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.atherosclerosis.2022.06.1022_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/dom.14700","article-title":"Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease","author":"Verma","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.atherosclerosis.2022.06.1022_bib16","article-title":"Patients with peripheral arterial disease in the CHARISMA trial","author":"Cacoub","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2022.06.1022_bib17","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","author":"Bonaca","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2022.06.1022_bib18","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2022.06.1022_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.119.044598","article-title":"Rivaroxaban plus aspirin versus aspirin alone in patients with prior percutaneous coronary intervention (COMPASS-PCI)","author":"Bainey","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.06.1022_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","author":"Anand","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.atherosclerosis.2022.06.1022_bib21","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022013211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022013211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:50:40Z","timestamp":1758156640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915022013211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":21,"alternative-id":["S0021915022013211"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.06.1022","relation":{},"ISSN":["0021-9150"],"issn-type":[{"type":"print","value":"0021-9150"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Percutaneous coronary intervention with peripheral artery disease in the contemporary era: Still life or limb?","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.06.1022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}